The Global Transcatheter Heart Valve Market is estimated to be USD 8.73 Bn in 2023 and is expected to reach USD 19.19 Bn by 2028 growing at a CAGR of 17.06%.Favorable reimbursement policies in the U.S. and European Union (EU) nations
A transcatheter heart valve is a medical device that replaces a diseased heart valve without opening heart surgery. A catheter, a long, thin tube placed into the heart after being steered through a blood artery in the groin or chest, is used to do this. Aortic stenosis is a disorder in which the valve that controls blood flow from the heart's left ventricle to the aorta narrows and stiffens, obstructing blood flow. Transcatheter heart valves are made to treat this issue. The valve comprises a collapsible frame and a biological valve leaflet composed of animal tissue. Transcatheter aortic valve replacement (TAVR) or transcatheter aortic valve implantation is the operation name to implant a transcatheter heart valve (TAVI). It usually takes a few hours to finish and is done with conscious sedation and local anesthetic.
The rising frequency of cardiovascular disorders primarily drives the global transcatheter heart valve market. Valvular heart disease significantly adds to the burden of cardiovascular disease, the world's leading cause of mortality. Age-related degeneration, congenital flaws, infections, or other underlying medical disorders can all lead to valvular heart disease. Patients with valvular heart disease at high risk for surgery prefer transcatheter heart valve replacement and repair operations because they provide a less intrusive alternative to conventional open-heart surgery.
Unfortunately, the market is restrained by the transcatheter heart valve's relatively expensive cost. Transcatheter aortic valve replacement (TAVR) devices typically cost USD 32,000, whereas surgical aortic valve replacement (SAVR) devices cost between USD 4,000 and USD 7,000. Moreover, TAVR carries various risks and drawbacks, such as artery damage from catheter insertion that can result in significant bleeding, valve leakage, infection, renal failure, heart attack, major stroke, and even death during the surgery.
However, the market has an opportunity due to advancements in developing transcatheter heart valve technologies. These developments have produced more dependable, secure, and simple implantable transcatheter heart valve products. These new materials are biocompatible and resistant to wear and tear. The market also includes the development of novel imaging and navigational technologies that enable more accurate placement of the heart valve.
- However, the market is challenged by a shortage of awareness of transcatheter heart valves and insufficient healthcare facilities. There is a problem with the lack of healthcare facilities that provide TAVR. The TAVR procedure is highly specialized and necessitates a sophisticated infrastructure. Nevertheless, not all hospitals have the equipment or skilled personnel to perform TAVR, which restricts the number of patients accessing this therapy option. Patients may have to travel long distances to undergo TAVR in such circumstances, which can be costly and uncomfortable. Patients who reside in rural or distant places, where there may be restricted access to facilities providing specialist healthcare, should be especially concerned about this.
Market Segmentations
- The Global Transcatheter Heart Valve Market is segmented based on Type, Technology, Indication, Surgical Approach, End-User, and Geography.
- By Type, the market is classified into Transcatheter Aortic Valve, Transcatheter Pulmonary Valve, and Transcatheter Mitral Valve.
- The Transcatheter Aortic Valve segment accounted for the maximum share, owing to the growing healthcare expenditure, increasing prevalence of chronic heart diseases, and increasing number of people with severe aortic stenosis. In addition, technological developments in tricuspid valve intervention, harpoon implementation, and neochord systems are among the significant reasons anticipated to increase usage rates over the forecast period. In addition, several clinical studies showing the value of transcatheter aortic valve replacement therapy for treating inoperable patients with aortic stenosis or other valvular disorders have sped up the adoption of this technique throughout the U.S. and EU countries.
- By Technology, the market is classified into Balloon Expanded Transcatheter Valves and Self-Expanded Transcatheter Valves.
- The Self-Expanded Transcatheter Valve Market accounted for the maximum share. This technique is the foundation for most first- and second-generation transcatheter heart valves, making up the most significant portion of the market. It is a particular kind of artificial heart valve put into the heart with the least amount of trauma. This valve is intended to replace a native heart valve that is sick or damaged and return to normal blood flow.
- By Surgical Approach, the market is classified into Transfemoral Approach, Transapical Approach, and Subclavian Approach.
- The Trans-Femoral Approach holds the maximum market share. It enables less intrusive access to the artery system, which lowers the risk of problems and speeds up patient recovery. The femoral artery, the major artery in the thigh that delivers blood to the lower limbs, is accessible using this surgical approach. This method makes a groin incision, and a catheter or other medical device is inserted through the femoral artery.
- By Indication, the market is classified into Aortic Stenosis, Mitral Regurgitation, Aortic Regurgitation, Mitral Stenosis, and Tricuspid Regurgitation.
- The Aortic Stenosis segment dominated the global market. Aortic stenosis is a disorder in which the heart's aortic valve narrows, limiting blood flow from the heart to the rest of the body. This could result in fainting, shortness of breath, and chest pain. The transcatheter aortic valve replacement (TAVR) method can replace a sick or damaged aortic valve without requiring open heart surgery.
- By End-User, the market is classified into Hospitals, Cardiac Catheterization Laboratories, and Ambulatory Surgical Centers.
- Transcatheter heart valve replacement and repair operations are frequently carried out at a medical facility. For patients with valvular heart disease, hospitals are frequently their first source of care. The diagnosis, patient selection, and post-procedure care of patients having transcatheter heart valve replacement and repair procedures are all handled by hospitals. In light of this, hospitals are significant market participants and play a crucial part in the total patient journey. The hospital's segment held a significant share of the global market.
- By Geography, the market is classified into the Americas, Europe, Middle East & Africa, and Asia-Pacific.
- Americas accounted for the majority share of the market. The main drivers of its large market share are the rising R&D expenditures and rising public awareness of cutting-edge transcatheter heart valve therapy. Additionally, this region's growth is fueled by a strong reimbursement framework, incentives for creating innovative products, and cooperation amongst diverse stakeholders. Most Americans live in the U.S., and the FDA's clearance of these medications is an essential step toward commercialization.
Recent Development
- Medtronic, Inc. acquired Affera to expand the cardiac ablation portfolio of the company, enabling the creation of maps to diagnose arrhythmias. - August 2022
- CryoLife acquired Ascyrus Medical, a company that develops devices for treating aortic disease, including transcatheter aortic valve replacement procedures. - September 2020
- JenaValve Technology received the U.S. FDA’s breakthrough device designation for its pericardial TAVR device. - January 2020
Company Profiles
The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are Abbott, Biotronik, Boston Scientific, Bracco, Braile Biomedica, Colibri Heart Valve, Cryolife, etc.Countries Studied
- America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
- Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Ireland, Luxembourg, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
- Middle East and Africa (Egypt, Israel, Qatar, Nigeria, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
- Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)
- The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.
Ansoff Analysis
- The report presents a detailed Ansoff matrix analysis for the Global Transcatheter Heart Valve Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.
- The publisher analyses the Global Transcatheter Heart Valve Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
- Based on the SWOT analysis conducted on the industry and industry players, the publisher has devised suitable strategies for market growth.
Why buy this report?
- The report offers a comprehensive evaluation of the Global Transcatheter Heart Valve Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
- The research report also provides a detailed market size analysis and projections in volume and value terms. The projections are calculated using verified research methodologies.
- Excel data sheet for the market size will also be provided with the report.
- The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
- The report includes an in-depth market analysis using Porter’s 5 forces model, PESTLE Analysis, and the Ansoff Matrix. In addition, the impact of COVID-19 on the market is also featured in the report.
- The report includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
- The report includes Self-Assessment Form, which helps customers evaluate their position in the market compared to their competitors.
- The report offers customized research - tailored uniquely to our customers with a quick turnaround time. We offer a 15% customization option at no extra charge to all our clients for any of our syndicated reports.
Report Highlights:
- A complete analysis of the market, including the parent industry
- Important market dynamics and trends
- Impact Analysis - a comprehensive assessment to confront risk and make strategic & operational decisions to counter the changes in the market environment.
- Market segmentation
- Competitive Analysis: Comparative analysis of competitor
- Historical, current, and projected size of the market based on value and volume
- Market size of the US states
- Market shares and strategies of key players
- Recommendations to companies for strengthening their foothold in the market
Table of Contents
1 Report Description
2 Research Methodology
3 Executive Summary
4 Market Dynamics
5 Market Analysis
6 Global Transcatheter Heart Valve Market, By Type
7 Global Transcatheter Heart Valve Market, By Technology
8 Global Transcatheter Heart Valve Market, By Indication
9 Global Transcatheter Heart Valve Market, By Surgical Approach
10 Global Transcatheter Heart Valve Market, By End-User
11 Americas' Transcatheter Heart Valve Market
12 Europe's Transcatheter Heart Valve Market
13 Middle East and Africa's Transcatheter Heart Valve Market
14 APAC's Transcatheter Heart Valve Market
15 Competitive Landscape
16 Company Profiles
17 Appendix
Companies Mentioned
- Abbott Laboratories
- Biotronik
- Boston Scientific Corp.
- Bracco Group
- Braile Biomedica
- Colibri Heart Valve, LLC
- Cryolife, Inc.
- Direct Flow Medical
- Edwards Lifesciences Corp.
- Hansen Medical
- HLT Medical
- Jenavalve Technology, Inc.
- Lepu Medical Technology Co., Ltd.
- LivaNova PLC
- Medtronic PLC
- Micro Interventional Devices, Inc.
- Neovasc, Inc.
- St. Jude Medical, Inc.
- Symetis SA
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 179 |
Published | February 2024 |
Forecast Period | 2023 - 2028 |
Estimated Market Value ( USD | $ 8.73 Billion |
Forecasted Market Value ( USD | $ 19.19 Billion |
Compound Annual Growth Rate | 17.0% |
Regions Covered | Global |
No. of Companies Mentioned | 19 |